XML 30 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating activities      
Net loss $ (95,154,000) $ (112,444,000) $ (106,794,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 3,244,000 2,257,000 1,365,000
Write-off of assets in progress   862,000  
(Gain) loss on disposal of property and equipment (10,000) 91,000 46,000
Accretion of discounts and amortization of premiums on marketable securities (193,000) 178,000 660,000
Reversal of deferred rent upon lease amendment (209,000)    
Accretion of debt discount related to debt financing     (115,000)
Cash-settled portion of stock compensation expense 0 602,000 387,000
Stock compensation expense 14,917,000 14,126,000 9,316,000
Amortization of intangible assets 1,194,000    
Loss on extinguishment of debt     1,671,000
Changes in operating assets and liabilities:      
Accounts and other receivables 488,000 52,000 (667,000)
Inventories (312,000)    
Prepaid expenses and other current assets (1,830,000) 560,000 1,631,000
Restricted cash and other assets (936,000) (103,000) (211,000)
Accounts payable (1,915,000) 1,181,000 1,246,000
Accrued liabilities and other long term liabilities 3,198,000 (11,759,000) 9,017,000
Deferred revenues   (2,654,000) (10,111,000)
Net cash used in operating activities (77,518,000) (107,051,000) (92,559,000)
Investing activities      
Purchases of marketable securities (227,672,000) (126,754,000) (208,936,000)
Proceeds from maturities of marketable securities 119,638,000 220,760,000 130,110,000
Purchases of property and equipment, net (669,000) (7,757,000) (6,970,000)
Net cash (used in) provided by investing activities (108,703,000) 86,249,000 (85,796,000)
Financing activities      
Proceeds from issuances of common stock, net 185,936,000   183,897,000
Payment of debt     (10,988,000)
Proceeds (withholding) from exercise of stock options and restricted stock awards, net 1,613,000 (84,000) 531,000
Proceeds from Employee Stock Purchase Plan 293,000 615,000 291,000
Proceeds from exercise of warrants     228,000
Net cash provided by financing activities 187,842,000 531,000 173,959,000
Effect of exchange rate changes on cash and cash equivalents 674,000 (252,000) (303,000)
Net increase (decrease) in cash and cash equivalents 2,295,000 (20,523,000) (4,699,000)
Cash and cash equivalents at beginning of year 24,289,000 44,812,000 49,511,000
Cash and cash equivalents at end of year 26,584,000 24,289,000 44,812,000
Supplemental disclosure of cash flow information      
Cash paid during the year for interest     720,000
Accrual for litigation settlement and insurance recovery (Note 9)   4,975,000  
Release of accrual for litigation settlement and insurance recovery (Note 9) 4,975,000    
Non-cash investing and financing activities:      
Disposal of fully depreciated property and equipment 86,000 2,354,000 1,436,000
Net change in unrealized (loss) gain on marketable securities $ (83,000) (8,000) $ 11,000
Astra Zeneca      
Supplemental disclosure of cash flow information      
Return of unused development funding to AstraZeneca AB (Note 10)   7,200,000  
Milestone payment from AstraZeneca AB (Note 10)   $ 7,200,000